Bridget N. Fahy, MD
Professor of Surgery
University of New Mexico, Division of Surgical Oncology
Albuquerque, New Mexico, United States
Disclosure: Align Tech, Inc (Individual(s) Involved: Self): Stockholder; Bristol-Myers Squibb; Dava Oncology; Illumina, Inc.; Imedex, LLC; MedIummune; and Merck & Co., Inc. (Individual(s) Involved: Self): Stockholder; Fulgent Genetics (Individual(s) Involved: Self): Stockholder; GoodRx Holdings (Individual(s) Involved: Self): Stockholder; Guardant Health, Inc. (Individual(s) Involved: Self): Stockholder; healthequity Inc (Individual(s) Involved: Self): Stockholder; Intuitive Surgical (Individual(s) Involved: Self): Stockholder; INVITAE CORP (Individual(s) Involved: Self): Stockholder, Stockholder; Masimo (Individual(s) Involved: Self): Stockholder; Moderna (Individual(s) Involved: Self): Stockholder; neurocrine bioscnce (Individual(s) Involved: Self): Stockholder; novocure Ltd (Individual(s) Involved: Self): Stockholder; quidel (Individual(s) Involved: Self): Stockholder; Repligen Corp (Individual(s) Involved: Self): Stockholder; ResMed Inc (Individual(s) Involved: Self): Stockholder; Seagen (Individual(s) Involved: Self): Stockholder; Shockwave Medical (Individual(s) Involved: Self): Stockholder; Staar Surgical Co (Individual(s) Involved: Self): Stockholder; Teladoc Health (Individual(s) Involved: Self): Stockholder; united healthcare (Individual(s) Involved: Self): Stockholder; Veeva Systems Inc (Individual(s) Involved: Self): Stockholder